Data for: A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study
Published: 09-01-2019| Version 1 | DOI: 10.17632/ffg8fv5ph5.1
Contributors:
Description
A phase II, multicenter, single-arm trial of eribulin as first-line therapy for aggressive taxane-pretreated HER2-negative metastatic breast cancer patients: The MERIBEL study